Biogen (BIIB) Tops Q2 EPS by $2.22, Guidance Beats

Biogen (NASDAQ: BIIB) reported Q2 EPS of $10.26, $2.22 better than the analyst estimate of $8.04. Revenue for the quarter came in at $3.68 billion versus the consensus estimate of $3.44 billion.

GUIDANCE:

Biogen sees FY2020 EPS of $34.00-$36.00, versus the consensus of $32.96. Biogen sees FY2020 revenue of $13.8-14.2 billion, versus the consensus of $13.94 billion.

For earnings history and earnings-related data on Biogen (BIIB) click here.

You May Also Be Interested In

• AeroVironment restates quarterly financials, citing $89M goodwill error
• AXT appoints Tracy Liu to its board of directors
• Ridgepost Capital acquires Stellus Capital Management for $4B AUM